Pfizer to Present Cancer Therapies at ASCO Annual Meeting, Including Advances in ADCs and Bispecific Antibodies
Pfizer to Present Cancer Therapies at ASCO Annual Meeting, Including Advances in ADCs and Bispecific Antibodies
輝瑞將在ASCO年會上介紹癌症療法，包括ADC和雙特異性抗體的進展
Pfizer Inc. (NYSE:PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 to June 4 in Chicago. More than 50abstracts, including 11oral presentations, will be presented from Pfizer's broadened portfolio of approved and pipeline therapies across the company's key tumor areas and core scientific modalities, including small molecules, antibody-drug conjugates (ADCs) and bispecific antibodies.
輝瑞公司（紐約證券交易所代碼：PFE）在5月31日至6月4日在芝加哥舉行的2024年美國臨床腫瘤學會（ASCO）年會上重點介紹了其在推進新的潛在腫瘤學護理標準方面取得的進展。輝瑞在公司關鍵腫瘤領域和核心科學模式（包括小分子、抗體藥物偶聯物（ADC）和雙特異性抗體）中擴大了已獲批准和在研的療法產品組合，將發表50多份摘要，包括11份口頭演講。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。